Raymond James analyst Michael Freeman raised the firm’s price target on NervGen Pharma (NGENF) to C$4.50 from C$3 and keeps a Market Perform rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGENF: